Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
CEO: Kevin A. Lobo. Company website
Stryker Corporation (SYK) trades at $275.12, down 1.79% on the day, as of Sep 20, 2026 15:01 UTC.
Stryker Corporation has a market capitalisation of $105.47B, calculated from the live SYK share price and shares outstanding.
SYK trades at a trailing P/E of 28.51, from earnings per share of $9.65 over the last twelve months.
Stryker Corporation generated revenue of $25.84B over the trailing twelve months, which puts the stock at 4.08 times sales.
Yes. Stryker Corporation pays a dividend yielding 0.94% on the current share price.
SYK has traded between $267.00 and $392.55 over the past 52 weeks, and the last price is 29.9% below that high.
Yes. Stryker Corporation keeps 14.43% of revenue as net income over the trailing twelve months.
Wall Street analysts rate SYK Buy, with an average price target of $371.65, 35.1% above the current price.
Stryker Corporation is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Kevin A. Lobo is the chief executive of Stryker Corporation, which employs 56,000 people.
QFI Terminal shows SYK with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open SYK in Terminal See plans